Jiangsu Hengrui Medicine Overview
- Year Founded
-
1970
- Status
-
Public
- Employees
-
20,602
- Stock Symbol
-
600276
- Investments
-
10
- Share Price
-
$7.19
- (As of Thursday Closing)
Jiangsu Hengrui Medicine General Information
Description
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
Contact Information
Website
www.hengrui.comCorporate Office
- Number 7 Kunlunshan Road
- Lianyungang Economic and Technological Development Zone, Jiangsu Province
- Shanghai, 200120
- China
Corporate Office
- Number 7 Kunlunshan Road
- Lianyungang Economic and Technological Development Zone, Jiangsu Province
- Shanghai, 200120
- China
Jiangsu Hengrui Medicine Stock Performance
As of 12-Nov-2026, Jiangsu Hengrui Medicine’s stock price is $7.19. Its current market cap is $47.5B with 6.64B shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $7.19 | $7.23 | $6.25 - $9.44 | $47.5B | 6.64B | 67.3M | $0.20 |
Jiangsu Hengrui Medicine Financials Summary
As of 30-Sep-2026, Jiangsu Hengrui Medicine has a trailing 12-month revenue of $4.77B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 40,859,911 | 50,982,388 | 37,060,030 | 38,200,367 |
| Revenue | 4,765,933 | 4,398,277 | 3,900,043 | 3,225,466 |
| EBITDA | 1,265,833 | 1,221,105 | 1,024,046 | 692,663 |
| Net Income | 1,288,799 | 1,072,273 | 883,083 | 608,128 |
| Total Assets | 11,444,355 | 9,985,753 | 6,867,803 | 6,176,750 |
| Total Debt | 62,898 | 10,610 | 15,090 | 10,605 |
Jiangsu Hengrui Medicine Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Jiangsu Hengrui Medicine Comparisons
Industry
Financing
Details
Jiangsu Hengrui Medicine Competitors (1)
One of Jiangsu Hengrui Medicine’s competitors is Abbott, a Corporation company based in Abbot Park, IL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Abbott | Corporation | Abbot Park, IL |
Jiangsu Hengrui Medicine Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Jiangsu Hengrui Medicine Patents
Jiangsu Hengrui Medicine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026228761-A1 | Crystalline form of 7,9-dihydrofuro[3,4-f]quinazoline compound, and preparation method therefor | Pending | 30-Apr-2025 | ||
| WO-2026228762-A1 | Protein and preparation method therefor | Pending | 30-Apr-2025 | ||
| WO-2026228549-A1 | Antigen-binding molecule specifically binding to cd38, conjugate comprising same, and medical use thereof | Pending | 27-Apr-2025 | ||
| WO-2026223755-A1 | Antigen-binding molecule specifically binding to gdf15 and pharmaceutical use thereof | Pending | 23-Apr-2025 | ||
| WO-2026223668-A1 | Engineered cysteine-substituted protein and conjugate containing same | Pending | 22-Apr-2025 |
Jiangsu Hengrui Medicine Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Jiangsu Hengrui Medicine Investments (10)
Jiangsu Hengrui Medicine’s most recent deal was a Corporate with Hercules (Pharmaceuticals). The deal was made on 20-May-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Hercules (Pharmaceuticals) | 20-May-2024 | Corporate | Distributors (Healthcare) | ||
| TargetingOne | 26-Jan-2024 | Later Stage VC | Diagnostic Equipment | ||
| YL-Pharma | 08-Nov-2023 | Later Stage VC | Pharmaceuticals | ||
| Hryz Bio Tech | 17-May-2023 | Later Stage VC | Drug Discovery | ||
| Ruihongdi Medicine | 24-Sep-2022 | Early Stage VC | Drug Discovery |
Jiangsu Hengrui Medicine ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
27.26 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Jiangsu Hengrui Medicine Exits (1)
Jiangsu Hengrui Medicine’s most recent exit was on 01-Jan-2020 from Ribogenics. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Ribogenics | 01-Jan-2020 | Completed |
|
Jiangsu Hengrui Medicine FAQs
-
When was Jiangsu Hengrui Medicine founded?
Jiangsu Hengrui Medicine was founded in 1970.
-
Where is Jiangsu Hengrui Medicine headquartered?
Jiangsu Hengrui Medicine is headquartered in Shanghai, China.
-
What is the size of Jiangsu Hengrui Medicine?
Jiangsu Hengrui Medicine has 20,602 total employees.
-
What industry is Jiangsu Hengrui Medicine in?
Jiangsu Hengrui Medicine’s primary industry is Medical Supplies.
-
Is Jiangsu Hengrui Medicine a private or public company?
Jiangsu Hengrui Medicine is a Public company.
-
What is Jiangsu Hengrui Medicine’s stock symbol?
The ticker symbol for Jiangsu Hengrui Medicine is 600276.
-
What is the current stock price of Jiangsu Hengrui Medicine?
As of 12-Nov-2026 the stock price of Jiangsu Hengrui Medicine is $7.19.
-
What is the current market cap of Jiangsu Hengrui Medicine?
The current market capitalization of Jiangsu Hengrui Medicine is $47.5B.
-
What is Jiangsu Hengrui Medicine’s current revenue?
The trailing twelve month revenue for Jiangsu Hengrui Medicine is $4.77B.
-
Who are Jiangsu Hengrui Medicine’s competitors?
Abbott is a competitor of Jiangsu Hengrui Medicine.
-
What is Jiangsu Hengrui Medicine’s annual earnings per share (EPS)?
Jiangsu Hengrui Medicine’s EPS for 12 months was $0.20.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
